Wafik S. El-Deiry: Dr. Susan Galbraith speaks about AstraZeneca oncology portfolio and collaboration opportunities at the AACR Oncology Industry Partnering Event in San Diego
Wafik S. El-Deiry,
“Listening to Dr. Susan Galbraith speaks about AstraZeneca oncology portfolio and collaboration opportunities at the American Association for Cancer Research (AACR) Oncology Industry Partnering Event in San Diego.
Dr. Galbraith shared AstraZeneca’s oncology portfolio at AACR24.
Dr. Susan Galbraith described:
Antibodies targeting multiple checkpoints represent next wave of IO including IO resistance at AstraZeneca.
Expanding Trastuzumab deruxtecan to pan-tumor biomarker driven.
Datopotamab deruxtecan in collab with Daiichi.
She discussed a number of ongoing collaborations with AstraZeneca.
Dr. Galbraith spoke about various AstraZeneca deals and collaborations across oncology targets, the growing portfolio of ‘differentiated ADC’s,’ AZD8205 data, AZP9592 in lung cancer.
AZD0901 in gastric cancer in a platform study looking at combos.
AZD0022 oral vs KRAS G12D entering trials.
Adding a CAR-T that may have less toxicity and progress in multiple myeloma along with an internal program in cell therapies at AstraZeneca.
Dr. Galbraith described NT-175 targeting p53 R175H in the clinic, emerging digital pathology that she mentioned earlier will be very important in oncology, Translational Medicine Collaborations, and directions in global digital health technologies.”
Source: Wafik S. El-Deiry/LinkedIn
